Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Efficacy and Safety of Erlotinib (Tarceva® ) Therapy in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) , Subtype Adenocarcinoma, Who Have Good Performance Status (PS 0-1) - ELEMENT

NCT01836133 is registered in ClinicalTrials.gov with Hoffmann-La Roche as lead sponsor.

NCT NCT01836133
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01836133 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Efficacy and Safety of Erlotinib (Tarceva® ) Therapy in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) , Subtype Adenocarcinoma, Who Have Good Performance Status (PS 0-1) - ELEMENT
Lead sponsor
Hoffmann-La Roche
Phase
Observational
Overall status
Completed
Start date
May 31, 2013
Completion date
January 31, 2016
Enrollment
70 (actual)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

non-squamous non-small cell lung cancer